These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 32866816

  • 1. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A, Alshareef M, Porto GBF, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D.
    J Neurol Sci; 2020 Nov 15; 418():117102. PubMed ID: 32866816
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma.
    Jin L, Kiang KM, Cheng SY, Leung GK.
    Lab Invest; 2022 Feb 15; 102(2):194-203. PubMed ID: 34625658
    [Abstract] [Full Text] [Related]

  • 3. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA.
    Neuro Oncol; 2021 Jun 01; 23(6):920-931. PubMed ID: 33433610
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.
    Neuro Oncol; 2013 Jun 01; 15(6):735-46. PubMed ID: 23479134
    [Abstract] [Full Text] [Related]

  • 5. Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p.
    Wu P, Cai J, Chen Q, Han B, Meng X, Li Y, Li Z, Wang R, Lin L, Duan C, Kang C, Jiang C.
    Nat Commun; 2019 May 03; 10(1):2045. PubMed ID: 31053733
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Müller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette JJD, Kurian KM, Schüller U, Petersen C, Rothkamm K, O Rourke DM, Short SC, Kriegs M.
    Oncogene; 2020 Apr 03; 39(15):3041-3055. PubMed ID: 32066879
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.
    J Neurooncol; 2009 Mar 03; 92(1):23-31. PubMed ID: 19011762
    [Abstract] [Full Text] [Related]

  • 9. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.
    Tumour Biol; 2013 Jun 03; 34(3):1935-47. PubMed ID: 23519841
    [Abstract] [Full Text] [Related]

  • 10. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q, Berglund AE, Macaulay RJ, Etame AB.
    Int J Mol Sci; 2023 Oct 14; 24(20):. PubMed ID: 37894860
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T, Tsuji S, Nakamura S, Egashira Y, Shimazawa M, Nakayama N, Yano H, Iwama T, Hara H.
    J Neurosurg; 2021 Mar 01; 134(3):701-710. PubMed ID: 32168477
    [Abstract] [Full Text] [Related]

  • 13. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M, Taşpınar F, Denizler-Ebiri FN, Castresana JS, Taşpınar M.
    Med Oncol; 2023 Jul 05; 40(8):223. PubMed ID: 37403006
    [Abstract] [Full Text] [Related]

  • 14. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S, Nakamura S, Shoda K, Yamada T, Shimazawa M, Nakayama N, Iwama T, Hara H.
    J Neurooncol; 2022 Nov 05; 160(2):375-388. PubMed ID: 36308592
    [Abstract] [Full Text] [Related]

  • 15. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F, Augello FR, Artone S, Gugu MK, Cifone MG, Cinque B, Palumbo P.
    Int J Mol Sci; 2022 Jan 28; 23(3):. PubMed ID: 35163465
    [Abstract] [Full Text] [Related]

  • 16. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
    Ganesa S, Sule A, Sundaram RK, Bindra RS.
    Sci Rep; 2022 Apr 06; 12(1):5827. PubMed ID: 35388070
    [Abstract] [Full Text] [Related]

  • 17. Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
    Wu M, Song D, Li H, Ahmad N, Xu H, Yang X, Wang Q, Cheng X, Deng S, Shu X.
    Int J Mol Sci; 2023 May 29; 24(11):. PubMed ID: 37298405
    [Abstract] [Full Text] [Related]

  • 18. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Xin L, Tan Y, Zhu Y, Cui X, Wang Q, Zhao J, Tian S, Xu C, Xiao M, Hong B, Xu J, Yuan X, Wang C, Kang C, Fang C.
    Neuro Oncol; 2023 Nov 02; 25(11):1976-1988. PubMed ID: 37279651
    [Abstract] [Full Text] [Related]

  • 19. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G, Sun Y, Hong R, Xiong J, Lu Y, Liu Y, Lu J, Zhang Z, Guo C, Nan Y, Huang Q.
    Clin Transl Oncol; 2020 Aug 02; 22(8):1252-1262. PubMed ID: 31865606
    [Abstract] [Full Text] [Related]

  • 20. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D, Leenstra S, van der Kaaij M, Villarreal A, Bello-Rivero I.
    Mol Biol Rep; 2020 Jul 02; 47(7):5263-5271. PubMed ID: 32607953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.